Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$18.8B
191M shares
52-week range
$79.12 – $106.88
64% from low
Sector
ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES
Exchange
NYSE
CS
P/S (TTM)
2.2
EV / FCF (TTM)
14.1
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
www.zimmerbiomet.comNo one on the platform currently holds ZBH.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 60,536 | $5.5M |
| Bridgewater Associatesas of 2026-03-31 | 33,993 | $3.1M |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-09-30 | $0.2400 | 2026-10-30 |
| 2026-06-25 | $0.2400 | 2026-07-31 |
| 2026-03-31 | $0.2400 | 2026-04-30 |
| 2025-12-30 | $0.2400 | 2026-01-30 |
| 2025-09-30 | $0.2400 | 2025-10-31 |
| 2025-06-26 | $0.2400 | 2025-07-31 |
| 2025-03-31 | $0.2400 | 2025-04-30 |
| 2024-12-30 | $0.2400 | 2025-01-31 |
| 2024-09-30 | $0.2400 | 2024-10-31 |
| 2024-06-26 | $0.2400 | 2024-07-31 |
No one on the platform has traded ZBH yet.
| 2024-03-27 | $0.2400 | 2024-04-30 |
| 2023-12-26 | $0.2400 | 2024-01-31 |
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 5.9% | 5.1% | — | — | — | |
| Rev. Growth % | 7.2% | 6.1% | ||||
| Profit Margin % | 8.6% | 8.7% | 7.8% | |||
| Free Cash Flow Margin % | 17.9% | 16.8% | 17.4% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +1.6% on the P/E track.
At today's price, your expected annual return is +6.1% on the P/E track.
At today's price, your expected annual return is +10.4% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $8.6B | +4.7% | $8.53 | $8.49–$8.56 | 11.3× | 16 |
| 2027 | $8.9B | +3.6% | $9.07 | $8.85–$9.42 | 10.7× | 16 |
| 2028 | $9.3B | +4.0% | $9.73 | $8.37–$11.26 | 10.0× | 9 |
| 2029 | $9.7B | +4.2% | $10.44 | $10.29–$10.60 | 9.3× | 3 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 8 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-05 | $2.01 | $2.07 | +3.0% |
| 2026-04-28 | $1.86 | $2.09 | +12.4% |
| 2026-02-10 | $2.38 | $2.42 | +1.7% |
| 2025-11-05 | $1.87 | $1.90 | +1.6% |
| 2025-08-07 | $1.98 | $2.07 | +4.5% |
| 2025-05-05 | $1.77 | $1.81 | +2.3% |
| 2025-02-06 | $2.30 | $2.31 | +0.4% |
| 2024-10-30 | $1.74 |
| $1.74 |
| +0.0% |
| $25.3B |
| — |
| LHLabcorp Holdings Inc. | $324.51 | +0.17% | $26.6B | — |
| SNNSmith & Nephew plc | $27.80 | -0.75% | $11.7B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$SINT $ZBH $SOLV Google estimate the revenue increase from a three way merger between these companies. The number reflect 25% increase in margins justified by Sintx Si3N4 ability to reduce HAI. Not sure how it estimated Sintx product sales but in a 360 Bioshield GPO with “Si3N4 Inside” it’s plausible.
View on StockTwits ↗
$SINT $ZBH $SOLV $MMM $TMO Example of a 360 degree Bioshield with "Sintx Inside"
View on StockTwits ↗
$ZBH So striker says their ortho business is Down yet ZB who increased their outlook gets drop today as well. Lol. F WS full of crooks.
View on StockTwits ↗$SINT $SOLV $ZBH That market capture is 2 years or so. It should grow rapidly after that as no product suite could compete against IP that is antipathogenic, bioactive encouraging bone and tissue healing, reduces metallosis, Hospital HAI, and improves imagining in additon to the base products already established.
View on StockTwits ↗
$ZBH Positive (85%): shares face upward price pressure because reported Q2 growth and a higher 2026 outlook give analysts a basis to raise forward revenue and earnings assumptions... Full AI impact map, source, and watch-next details: https://nimpact.tech/newsimpact/news/fee7ca82aecd5026?utm_source=stocktwits&utm_medium=story_url
View on StockTwits ↗
https://www.marketbeat.com/earnings/reports/2026-8-5-zimmer-biomet-holdings-inc-stock/ $ZBH Zimmer Biomet Earnings Transcript
View on StockTwits ↗
$ZBH Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $1.03 up 33.77% YoY • Reported revenue of $2.18B up 4.80% YoY • Zimmer Biomet Holdings, Inc. updated its full-year 2026 guidance, raising reported revenue growth to 3.9%-4.9% and adjusted diluted EPS to a range of $8.47-$8.59, reflecting confidence in its ongoing business momentum.
View on StockTwits ↗
$ZBH Clown stock with MM bullshit. Put in a stop loss and they instantly hunt you.
View on StockTwits ↗$ZBH Ivan lets see if your arrogant ass can bring the good Old Brian days. Did you not learned anything from him?
View on StockTwits ↗
$CNMD $ZBH no way $ZBH buys cnmd. Margin and growth do not meet their strategic targets.
View on StockTwits ↗
Needham (Hold) says a $CNMD sale makes sense, citing steady mid-single-digit growth, significant recurring revenue, and an undervalued stock price. The firm expects a substantial premium, potentially reaching $46–$53 per share. $ZBH could be a strong potential buyer.
View on StockTwits ↗
$ZBH BMO Capital Markets has altered their rating of "Market Perform" and target of "$95" see consensus outlook
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.